Abstract
The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st-3rd relapse of multiple myeloma (MM) to a transplant arm (n = 139) consisting of 3 Rd (lenalidomide 25 mg, day 1-21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m2), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n = 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95% CI 0.65-1.16; p = 0.34). Median OS was not reached in the transplant and 62.7 months in the control arm (HR 0.81; 95% CI 0.52-1.28; p = 0.37). Forty-one patients (29%) did not receive the assigned sHDCT/ASCT mainly due to early disease progression, adverse events, and withdrawal of consent. Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p = 0.0087/0.0057) in patients who received sHDCT/ASCT. Incorporation of sHDCT/ASCT into relapse treatment with Rd was feasible in 71% of patients and d...Continue Reading
References
Jul 11, 1996·The New England Journal of Medicine·M AttalR Bataille
Sep 30, 1998·British Journal of Haematology·J BladéD Vesole
May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Jul 21, 2006·Leukemia·B G M DurieUNKNOWN International Myeloma Working Group
Oct 9, 2007·Lancet·Thierry FaconUNKNOWN Intergroupe Francophone du Myélome
Nov 23, 2007·The New England Journal of Medicine·Meletios DimopoulosUNKNOWN Multiple Myeloma (010) Study Investigators
Nov 23, 2007·The New England Journal of Medicine·Donna M WeberUNKNOWN Multiple Myeloma (009) Study Investigators
Mar 24, 2009·European Journal of Haematology·Edward A StadtmauerMeletios A Dimopoulos
Oct 27, 2009·The Lancet Oncology·S Vincent RajkumarUNKNOWN Eastern Cooperative Oncology Group
Mar 12, 2010·Haematologica·Kai NebenHartmut Goldschmidt
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Oct 12, 2013·British Journal of Haematology·Djordje Atanackovic, Georgia Schilling
Jun 21, 2014·The Lancet Oncology·Gordon CookUNKNOWN National Cancer Research Institute Haemato-oncology Clinical Studies Group
Jun 3, 2015·The New England Journal of Medicine·Sagar LonialUNKNOWN ELOQUENT-2 Investigators
Apr 27, 2016·BMC Cancer·Marc-Andrea BaertschHartmut Goldschmidt
Apr 28, 2016·The New England Journal of Medicine·Philippe MoreauUNKNOWN TOURMALINE-MM1 Study Group
Jul 5, 2016·The Lancet. Haematology·Gordon CookUNKNOWN National Cancer Research Institute Haemato-oncology Clinical Studies Group
Oct 6, 2016·The New England Journal of Medicine·Meletios A DimopoulosUNKNOWN POLLUX Investigators
Feb 12, 2017·Journal of the National Comprehensive Cancer Network : JNCCN·Shaji K KumarRashmi Kumar
Apr 4, 2017·European Journal of Haematology·Marc-Andrea BaertschPatrick Wuchter
Apr 6, 2017·The New England Journal of Medicine·Michel AttalUNKNOWN IFM 2009 Study
Jul 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip L McCarthyMichel Attal
Dec 9, 2017·Haematologica·Francesca GayPieter Sonneveld
Citations
Jan 13, 2021·Annals of Hematology·Leonardo Javier Arcuri, Andre Dias Americo
Jan 31, 2021·Bone Marrow Transplantation·Nausheen AhmedBrenda W Cooper
Feb 8, 2021·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A DimopoulosUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Feb 16, 2021·Open Medicine·Umit Yavuz MalkanHakan Goker
Mar 5, 2021·The Lancet Oncology·Philippe MoreauPaul G Richardson
Mar 30, 2021·Transplantation and Cellular Therapy·Emily C LiangSurbhi Sidana
Jun 3, 2021·Cancers·Fredrik Schjesvold, Albert Oriol
Jun 25, 2021·Bone Marrow Transplantation·Christopher LemieuxSurbhi Sidana
Jun 16, 2021·European Journal of Haematology·Donna E ReeceChristopher P Venner
Aug 5, 2021·Leukemia & Lymphoma·Huw RichardsNeil Rabin
Sep 24, 2021·Blood Cancer Journal·Matthew HoShaji Kumar
Sep 19, 2021·European Journal of Haematology·Henrik GregersenNina Gulbrandsen